Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?
Keywords:
sarcopenia, the European Working Group on Sarcopenia (EWGSOP), SARC-FAbstract
Sarcopenia, as defined by the European Working Group on Sarcopenia (EWGSOP) in Older People is “a progressive and generalized skeletal muscle disorder that is associated with increased likelihood of adverse outcomes including falls, fractures, physical disability, and mortality”. The first EWGSOP and Asian Working Group for Sarcopenia used muscle mass to define sarcopenia, which is diagnosed by using Dual-energy X-Ray absorptiometry (DXA). However, the cut-off from several countries in Asian showed different cut-off value for different age groups and BMI. In addition, not all hospitals and countries can afford DXA to be used as daily diagnostic routine for sarcopenia.In 2018, EWGSOP made a revision regarding sarcopenia, as well as the diagnostic test and cut-off value (EWGSOP2). EWGSOP2 recommends using self-questionnaire, known as SARC-F as sarcopenia screening, especially in community-dwelling elderly. SARC-F consisted of 5 questions regarding patient’s perception of his or her limitations in strength, walking ability, rising from a chair, stair climbing and experiences with falls. This is more feasible to be done in countries without advanced muscle mass measurement tools. Several parameters in sarcopenia are muscle strength, muscle quantity, and physical performance. In muscle strength, measuring grip strength can be done as predictor for patients’ outcomes, such as hospitalization and quality of life. For muscle quantity, the gold standards are Magnetic resonance imaging (MRI) and computed tomography (CT). However, since both are expensive, and the cut-off points have not been defined yet, DXA and Bioelectrical impedance analysis (BIA) can be a substitute. Current evidence showed that DXA still does not give consistent results and not yet portable for the use in the community. On the other hand, BIA measure muscle mass using the whole-body electrical conductivity and less expensive than the other tools, thus can be used in the community setting. However, there is no specific cut-off for BIA especially in elderly. For physical performance, several tests can be done, such as gait speed and Timed-Up and Go test (TUG).References
Cruz-Jentoft A, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48:16-31.
Chen LK, Lee WJ, Peng LN. Recent Advances in Sarcopenia Research in Asia: 2016 Update From the Asian Working Group for Sarcopenia. JAMDA. 2016;17(767);e1-767.e7.
Downloads
Published
2019-08-05
How to Cite
Setiati, S. (2019). Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?. Acta Medica Indonesiana, 51(2), 93. Retrieved from https://www.actamedindones.org/index.php/ijim/article/view/1223
Issue
Section
EDITORIAL
License
CopyrightThe authors who publish this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.